Table of Contents
3 - 6 ماہ کے لیے بہترین میوچل فنڈ
3 سے 6 ماہ کی مختصر مدت کے لیے، آپ یا تو اپنے پیسے کو پارک کر سکتے ہیں۔مائع باہمی فنڈز یا انتہائی مختصر مدتقرض باہمی فنڈ. مائعباہمی چندہ عام طور پر سرکاری سیکیورٹیز میں سرمایہ کاری کرتے ہیں اور 3 ماہ تک کی مدت کے ڈپازٹ کے سرٹیفکیٹ۔
تاہم اگر کوئی زیادہ منافع کے لیے خطرہ مول لینے کا خواہشمند ہے تو ذیل میں چند اختیارات کو دیکھ سکتا ہے۔
ٹاپ 5 ہاٹ میوچل فنڈز 3 ماہ
ذیل کی فہرست ہے۔بہترین باہمی فنڈز خالص اثاثے ختم ہونا100 کروڑ اور پچھلے 3 مہینوں میں بہترین منافع دیا ہے۔
The Investment objective of the Scheme is to provide investors with the opportunities for long-term capital appreciation by investing in a diversified portfolio of Equity and Equity related Instruments across market capitalization. However there can be no assurance that the investment objective under the Scheme will be realized IDBI Diversified Equity Fund is a Equity - Multi Cap fund was launched on 28 Mar 14. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Diversified Equity Fund Returns up to 1 year are on The Scheme will seek to invest predominantly in a diversified portfolio of equity and equity related instruments with the objective to provide investors with opportunities for capital appreciation and income along with the benefit of income-tax deduction(under section 80C of the Income-tax Act, 1961) on their investments. Investments in this scheme would be subject to a statutory lock-in of 3 years from the date of allotment to be eligible for income-tax benefits under Section 80C. There can be no assurance that the investment objective under the scheme will be realized. IDBI Equity Advantage Fund is a Equity - ELSS fund was launched on 10 Sep 13. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Equity Advantage Fund Returns up to 1 year are on The Investment objective of the Scheme is to provide investors with the opportunities for long-term capital appreciation by investing predominantly in Equity and Equity related Instruments of Large Cap companies. However
there can be no assurance that the investment objective under the Scheme will be realized. IDBI India Top 100 Equity Fund is a Equity - Large Cap fund was launched on 15 May 12. It is a fund with Moderately High risk and has given a Below is the key information for IDBI India Top 100 Equity Fund Returns up to 1 year are on The investment objective of the scheme is to invest in the stocks and equity related instruments comprising the S&P CNX Nifty Index in the same weights as these stocks represented in the Index with the intent to replicate the performance of the Total Returns Index of S&P CNX Nifty index. The scheme will adopt a passive investment strategy and will seek to achieve the investment objective by minimizing the tracking error between the S&P CNX Nifty index (Total Returns Index) and the scheme. IDBI Nifty Index Fund is a Others - Index Fund fund was launched on 25 Jun 10. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Nifty Index Fund Returns up to 1 year are on (Erstwhile IDBI Prudence Fund) The investment objective of the scheme would be to generate opportunities for capital appreciation along with income by investing in a diversified basket of equity and equity related instruments, debt and money market instruments. However, there can be no assurance that the investment objective of the scheme will be realized. IDBI Hybrid Equity Fund is a Hybrid - Hybrid Equity fund was launched on 24 Oct 16. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Hybrid Equity Fund Returns up to 1 year are on 1. IDBI Diversified Equity Fund
CAGR/Annualized return of 15.4% since its launch. Ranked 56 in Multi Cap category. . IDBI Diversified Equity Fund
Growth Launch Date 28 Mar 14 NAV (28 Jul 23) ₹37.99 ↑ 0.14 (0.37 %) Net Assets (Cr) ₹382 on 30 Jun 23 Category Equity - Multi Cap AMC IDBI Asset Management Limited Rating ☆☆ Risk Moderately High Expense Ratio 2.46 Sharpe Ratio 1.01 Information Ratio -0.53 Alpha Ratio -1.07 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹11,050 30 Nov 21 ₹15,516 30 Nov 22 ₹16,530 Returns for IDBI Diversified Equity Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 2.4% 3 Month 10.2% 6 Month 13.2% 1 Year 13.5% 3 Year 22.7% 5 Year 12% 10 Year 15 Year Since launch 15.4% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Diversified Equity Fund
Name Since Tenure Data below for IDBI Diversified Equity Fund as on 30 Jun 23
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 2. IDBI Equity Advantage Fund
CAGR/Annualized return of 16% since its launch. Ranked 21 in ELSS category. . IDBI Equity Advantage Fund
Growth Launch Date 10 Sep 13 NAV (28 Jul 23) ₹43.39 ↑ 0.04 (0.09 %) Net Assets (Cr) ₹485 on 30 Jun 23 Category Equity - ELSS AMC IDBI Asset Management Limited Rating ☆☆☆ Risk Moderately High Expense Ratio 2.39 Sharpe Ratio 1.21 Information Ratio -1.13 Alpha Ratio 1.78 Min Investment 500 Min SIP Investment 500 Exit Load NIL Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹10,309 30 Nov 21 ₹13,283 30 Nov 22 ₹14,560 Returns for IDBI Equity Advantage Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 3.1% 3 Month 9.7% 6 Month 15.1% 1 Year 16.9% 3 Year 20.8% 5 Year 10% 10 Year 15 Year Since launch 16% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Equity Advantage Fund
Name Since Tenure Data below for IDBI Equity Advantage Fund as on 30 Jun 23
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 3. IDBI India Top 100 Equity Fund
CAGR/Annualized return of 14.2% since its launch. Ranked 45 in Large Cap category. . IDBI India Top 100 Equity Fund
Growth Launch Date 15 May 12 NAV (28 Jul 23) ₹44.16 ↑ 0.05 (0.11 %) Net Assets (Cr) ₹655 on 30 Jun 23 Category Equity - Large Cap AMC IDBI Asset Management Limited Rating ☆☆☆ Risk Moderately High Expense Ratio 2.47 Sharpe Ratio 1.09 Information Ratio 0.14 Alpha Ratio 2.11 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹10,938 30 Nov 21 ₹14,930 30 Nov 22 ₹16,438 Returns for IDBI India Top 100 Equity Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 3% 3 Month 9.2% 6 Month 12.5% 1 Year 15.4% 3 Year 21.9% 5 Year 12.6% 10 Year 15 Year Since launch 14.2% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI India Top 100 Equity Fund
Name Since Tenure Data below for IDBI India Top 100 Equity Fund as on 30 Jun 23
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 4. IDBI Nifty Index Fund
CAGR/Annualized return of 10.3% since its launch. Ranked 83 in Index Fund category. . IDBI Nifty Index Fund
Growth Launch Date 25 Jun 10 NAV (28 Jul 23) ₹36.2111 ↓ -0.02 (-0.06 %) Net Assets (Cr) ₹208 on 30 Jun 23 Category Others - Index Fund AMC IDBI Asset Management Limited Rating ☆ Risk Moderately High Expense Ratio 0.9 Sharpe Ratio 1.04 Information Ratio -3.93 Alpha Ratio -1.03 Min Investment 5,000 Min SIP Investment 500 Exit Load NIL Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹10,732 30 Nov 21 ₹13,982 30 Nov 22 ₹15,500 Returns for IDBI Nifty Index Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 3.7% 3 Month 9.1% 6 Month 11.9% 1 Year 16.2% 3 Year 20.3% 5 Year 11.7% 10 Year 15 Year Since launch 10.3% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Nifty Index Fund
Name Since Tenure Data below for IDBI Nifty Index Fund as on 30 Jun 23
Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 5. IDBI Hybrid Equity Fund
CAGR/Annualized return of 8.3% since its launch. . IDBI Hybrid Equity Fund
Growth Launch Date 24 Oct 16 NAV (28 Jul 23) ₹17.1253 ↓ -0.01 (-0.05 %) Net Assets (Cr) ₹179 on 30 Jun 23 Category Hybrid - Hybrid Equity AMC IDBI Asset Management Limited Rating Risk Moderately High Expense Ratio 2.52 Sharpe Ratio 1.03 Information Ratio -1.03 Alpha Ratio -0.26 Min Investment 5,000 Min SIP Investment 500 Exit Load NIL Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹11,238 30 Nov 21 ₹13,946 30 Nov 22 ₹14,347 Returns for IDBI Hybrid Equity Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 2.1% 3 Month 7.8% 6 Month 9.8% 1 Year 12.1% 3 Year 14.4% 5 Year 7.1% 10 Year 15 Year Since launch 8.3% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Hybrid Equity Fund
Name Since Tenure Data below for IDBI Hybrid Equity Fund as on 30 Jun 23
Asset Allocation
Asset Class Value Equity Sector Allocation
Sector Value Debt Sector Allocation
Sector Value Credit Quality
Rating Value Top Securities Holdings / Portfolio
Name Holding Value Quantity
ٹاپ 5 ہاٹ میوچل فنڈز 6 ماہ
ذیل میں بہترین میوچل فنڈز کی فہرست ہے جن کے پاس خالص اثاثے ہیں۔100 کروڑ اور پچھلے 6 مہینوں میں بہترین منافع دیا ہے۔
(Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on (Erstwhile SBI IT Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. SBI Technology Opportunities Fund is a Equity - Sectoral fund was launched on 9 Jan 13. It is a fund with High risk and has given a Below is the key information for SBI Technology Opportunities Fund Returns up to 1 year are on (Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund was launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in Information Technology Sector in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA Digital India Fund is a Equity - Sectoral fund was launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA Digital India Fund Returns up to 1 year are on 1. UTI Healthcare Fund
CAGR/Annualized return of 15.4% since its launch. Ranked 40 in Sectoral category. Return for 2023 was 38.2% , 2022 was -12.3% and 2021 was 19.1% . UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (27 Dec 24) ₹291.213 ↑ 3.33 (1.16 %) Net Assets (Cr) ₹1,203 on 30 Nov 24 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.38 Sharpe Ratio 2.43 Information Ratio 0.1 Alpha Ratio 0.54 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹15,670 30 Nov 21 ₹19,186 30 Nov 22 ₹18,040 30 Nov 23 ₹23,340 30 Nov 24 ₹33,757 Returns for UTI Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 27 Dec 24 Duration Returns 1 Month 2.6% 3 Month 0.3% 6 Month 24.4% 1 Year 43.1% 3 Year 21.4% 5 Year 28% 10 Year 15 Year Since launch 15.4% Historical performance (Yearly) on absolute basis
Year Returns 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% 2015 12.4% 2014 43.7% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Kamal Gada 2 May 22 2.59 Yr. Data below for UTI Healthcare Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Health Care 96.07% Basic Materials 1.42% Financial Services 0.39% Asset Allocation
Asset Class Value Cash 2.12% Equity 97.88% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA11% ₹129 Cr 725,000 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | CIPLA6% ₹69 Cr 450,660 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | AJANTPHARM5% ₹58 Cr 193,047
↓ -15,318 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY5% ₹57 Cr 470,234
↑ 34,734 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | GLENMARK4% ₹47 Cr 309,311
↑ 58,980 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹46 Cr 266,306 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP3% ₹41 Cr 60,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | FORTIS3% ₹40 Cr 611,658
↓ -22,787 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL3% ₹38 Cr 74,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB3% ₹38 Cr 61,480 2. SBI Technology Opportunities Fund
CAGR/Annualized return of 21.1% since its launch. Ranked 42 in Sectoral category. Return for 2023 was 24.8% , 2022 was -15.5% and 2021 was 66.4% . SBI Technology Opportunities Fund
Growth Launch Date 9 Jan 13 NAV (26 Dec 24) ₹226.753 ↑ 0.20 (0.09 %) Net Assets (Cr) ₹4,586 on 30 Nov 24 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆ Risk High Expense Ratio 1.99 Sharpe Ratio 1.42 Information Ratio 0.39 Alpha Ratio 2.51 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹13,591 30 Nov 21 ₹23,898 30 Nov 22 ₹22,115 30 Nov 23 ₹25,178 30 Nov 24 ₹33,705 Returns for SBI Technology Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 27 Dec 24 Duration Returns 1 Month 2.8% 3 Month 3.3% 6 Month 21.4% 1 Year 31.1% 3 Year 12% 5 Year 27.6% 10 Year 15 Year Since launch 21.1% Historical performance (Yearly) on absolute basis
Year Returns 2023 24.8% 2022 -15.5% 2021 66.4% 2020 47.3% 2019 12.2% 2018 17.1% 2017 13% 2016 -3.3% 2015 2.4% 2014 29.2% Fund Manager information for SBI Technology Opportunities Fund
Name Since Tenure Pradeep Kesavan 1 Apr 24 0.67 Yr. Vivek Gedda 1 Apr 24 0.67 Yr. Data below for SBI Technology Opportunities Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Technology 57.69% Communication Services 24.5% Consumer Cyclical 6.56% Financial Services 2.89% Industrials 2.12% Consumer Defensive 1.12% Health Care 0.71% Asset Allocation
Asset Class Value Cash 1.65% Equity 98.35% Top Securities Holdings / Portfolio
Name Holding Value Quantity Infosys Ltd (Technology)
Equity, Since 31 Jan 03 | INFY24% ₹1,115 Cr 6,000,000 Bharti Airtel Ltd (Communication Services)
Equity, Since 31 May 18 | BHARTIARTL10% ₹472 Cr 2,900,000 Firstsource Solutions Ltd (Technology)
Equity, Since 31 Mar 23 | FSL6% ₹280 Cr 7,645,887 Coforge Ltd (Technology)
Equity, Since 31 Aug 23 | COFORGE6% ₹264 Cr 304,454 Tata Consultancy Services Ltd (Technology)
Equity, Since 30 Apr 06 | TCS5% ₹214 Cr 500,000
↓ -200,000 Zomato Ltd (Consumer Cyclical)
Equity, Since 31 Aug 24 | 5433204% ₹184 Cr 6,583,400
↑ 1,583,400 Cognizant Technology Solutions Corp Class A (Technology)
Equity, Since 31 Jul 23 | CTSH4% ₹173 Cr 254,000 Netflix Inc (Communication Services)
Equity, Since 31 Aug 21 | NFLX3% ₹150 Cr 20,000 Microsoft Corp (Technology)
Equity, Since 31 Aug 20 | MSFT3% ₹136 Cr 38,000 PB Fintech Ltd (Financial Services)
Equity, Since 30 Apr 24 | 5433903% ₹133 Cr 700,000 3. SBI Healthcare Opportunities Fund
CAGR/Annualized return of 16% since its launch. Ranked 34 in Sectoral category. Return for 2023 was 38.2% , 2022 was -6% and 2021 was 20.1% . SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (26 Dec 24) ₹429.269 ↑ 1.94 (0.45 %) Net Assets (Cr) ₹3,460 on 30 Nov 24 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 2.09 Sharpe Ratio 2.85 Information Ratio 0.75 Alpha Ratio 5.08 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹15,482 30 Nov 21 ₹18,848 30 Nov 22 ₹19,211 30 Nov 23 ₹24,570 30 Nov 24 ₹35,381 Returns for SBI Healthcare Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 27 Dec 24 Duration Returns 1 Month 2.5% 3 Month 2.4% 6 Month 21.1% 1 Year 41.4% 3 Year 24.1% 5 Year 29.6% 10 Year 15 Year Since launch 16% Historical performance (Yearly) on absolute basis
Year Returns 2023 38.2% 2022 -6% 2021 20.1% 2020 65.8% 2019 -0.5% 2018 -9.9% 2017 2.1% 2016 -14% 2015 27.1% 2014 56.8% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 13.51 Yr. Pradeep Kesavan 31 Dec 23 0.92 Yr. Data below for SBI Healthcare Opportunities Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Health Care 89.92% Basic Materials 6.58% Asset Allocation
Asset Class Value Cash 3.5% Equity 96.5% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA13% ₹445 Cr 2,500,000
↑ 100,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB6% ₹222 Cr 360,000 Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | CIPLA6% ₹196 Cr 1,280,000
↑ 280,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH6% ₹196 Cr 2,000,000
↓ -100,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | LUPIN5% ₹164 Cr 800,000 Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LZAGY4% ₹152 Cr 300,000 Poly Medicure Ltd (Healthcare)
Equity, Since 31 Aug 24 | POLYMED4% ₹139 Cr 500,000
↓ -140,000 Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Nov 22 | 5433084% ₹130 Cr 2,200,000
↓ -300,000 Jupiter Life Line Hospitals Ltd (Healthcare)
Equity, Since 31 Aug 23 | JLHL4% ₹126 Cr 832,871
↓ -67,129 Aether Industries Ltd (Basic Materials)
Equity, Since 31 May 22 | 5435343% ₹115 Cr 1,400,000 4. TATA India Pharma & Healthcare Fund
CAGR/Annualized return of 13.5% since its launch. Return for 2023 was 36.6% , 2022 was -8% and 2021 was 19.1% . TATA India Pharma & Healthcare Fund
Growth Launch Date 28 Dec 15 NAV (27 Dec 24) ₹31.3224 ↑ 0.38 (1.23 %) Net Assets (Cr) ₹1,214 on 30 Nov 24 Category Equity - Sectoral AMC Tata Asset Management Limited Rating Risk High Expense Ratio 0 Sharpe Ratio 2.17 Information Ratio 0.55 Alpha Ratio 4.58 Min Investment 5,000 Min SIP Investment 150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹15,116 30 Nov 21 ₹18,778 30 Nov 22 ₹18,383 30 Nov 23 ₹23,378 30 Nov 24 ₹32,641 Returns for TATA India Pharma & Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 27 Dec 24 Duration Returns 1 Month 4.9% 3 Month -0.2% 6 Month 20.5% 1 Year 40.1% 3 Year 22% 5 Year 27.8% 10 Year 15 Year Since launch 13.5% Historical performance (Yearly) on absolute basis
Year Returns 2023 36.6% 2022 -8% 2021 19.1% 2020 64.4% 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% 2015 2014 Fund Manager information for TATA India Pharma & Healthcare Fund
Name Since Tenure Meeta Shetty 9 Mar 21 3.73 Yr. Rajat Srivastava 16 Sep 24 0.21 Yr. Data below for TATA India Pharma & Healthcare Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Health Care 92.58% Basic Materials 2.04% Asset Allocation
Asset Class Value Cash 5.38% Equity 94.62% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA12% ₹149 Cr 804,300 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMA9% ₹103 Cr 741,000 Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | 5002577% ₹90 Cr 410,240 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | DRREDDY6% ₹78 Cr 614,555 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 5000876% ₹76 Cr 490,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB5% ₹62 Cr 104,965 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Oct 20 | 5328434% ₹53 Cr 855,100 Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Dec 22 | 5323214% ₹47 Cr 471,287 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEM4% ₹43 Cr 75,249 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP3% ₹41 Cr 58,903 5. TATA Digital India Fund
CAGR/Annualized return of 20.7% since its launch. Return for 2023 was 31.9% , 2022 was -23.3% and 2021 was 74.4% . TATA Digital India Fund
Growth Launch Date 28 Dec 15 NAV (27 Dec 24) ₹54.1921 ↑ 0.01 (0.01 %) Net Assets (Cr) ₹12,659 on 30 Nov 24 Category Equity - Sectoral AMC Tata Asset Management Limited Rating Risk High Expense Ratio 0 Sharpe Ratio 1.53 Information Ratio 0.66 Alpha Ratio 7.74 Min Investment 5,000 Min SIP Investment 150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Nov 19 ₹10,000 30 Nov 20 ₹14,034 30 Nov 21 ₹25,767 30 Nov 22 ₹22,715 30 Nov 23 ₹26,174 30 Nov 24 ₹36,503 Returns for TATA Digital India Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 27 Dec 24 Duration Returns 1 Month 0% 3 Month 3.2% 6 Month 20.1% 1 Year 30.7% 3 Year 10.7% 5 Year 28.9% 10 Year 15 Year Since launch 20.7% Historical performance (Yearly) on absolute basis
Year Returns 2023 31.9% 2022 -23.3% 2021 74.4% 2020 54.8% 2019 7.5% 2018 24.9% 2017 19.6% 2016 -6% 2015 2014 Fund Manager information for TATA Digital India Fund
Name Since Tenure Meeta Shetty 9 Mar 21 3.73 Yr. Kapil Malhotra 19 Dec 23 0.95 Yr. Data below for TATA Digital India Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Technology 74.58% Consumer Cyclical 6.93% Industrials 5.6% Communication Services 4.42% Financial Services 3.47% Asset Allocation
Asset Class Value Cash 5.01% Equity 94.99% Top Securities Holdings / Portfolio
Name Holding Value Quantity Infosys Ltd (Technology)
Equity, Since 31 Jan 16 | INFY17% ₹2,026 Cr 11,530,857 Tata Consultancy Services Ltd (Technology)
Equity, Since 31 Jan 16 | TCS10% ₹1,224 Cr 3,083,873
↑ 450,000 Tech Mahindra Ltd (Technology)
Equity, Since 30 Apr 16 | 53275510% ₹1,150 Cr 7,145,933 Wipro Ltd (Technology)
Equity, Since 31 Jul 18 | 5076858% ₹905 Cr 16,393,662
↑ 1,150,000 HCL Technologies Ltd (Technology)
Equity, Since 31 Jan 16 | HCLTECH7% ₹880 Cr 4,983,886 Zomato Ltd (Consumer Cyclical)
Equity, Since 31 Oct 22 | 5433206% ₹703 Cr 29,067,000 LTIMindtree Ltd (Technology)
Equity, Since 28 Feb 21 | LTIM5% ₹564 Cr 988,062 Persistent Systems Ltd (Technology)
Equity, Since 31 Jan 16 | PERSISTENT3% ₹408 Cr 759,192 Firstsource Solutions Ltd (Technology)
Equity, Since 30 Nov 21 | FSL3% ₹344 Cr 10,123,112 Sonata Software Ltd (Technology)
Equity, Since 30 Jun 23 | SONATSOFTW3% ₹314 Cr 5,125,514
↑ 445,517
میوچل فنڈز میں آن لائن سرمایہ کاری کیسے کی جائے؟
Fincash.com پر لائف ٹائم کے لیے مفت انویسٹمنٹ اکاؤنٹ کھولیں۔
اپنی رجسٹریشن اور KYC کا عمل مکمل کریں۔
دستاویزات اپ لوڈ کریں (PAN، آدھار، وغیرہ)۔اور، آپ سرمایہ کاری کے لیے تیار ہیں!
یہاں فراہم کردہ معلومات کے درست ہونے کو یقینی بنانے کے لیے تمام کوششیں کی گئی ہیں۔ تاہم، ڈیٹا کی درستگی کے حوالے سے کوئی ضمانت نہیں دی جاتی ہے۔ براہ کرم کوئی بھی سرمایہ کاری کرنے سے پہلے اسکیم کی معلومات کے دستاویز کے ساتھ تصدیق کریں۔
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2024 Shepard Technologies Private Limited. All Rights Reserved